MESOBLAST LTD
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Mesoblast
Biological Products, (No Diagnostic Substances), SIC 2836
Mesoblast Limited is a commercial-stage biotechnology company focused on developing and commercializing allogeneic cellular medicines. The company utilizes proprietary technology based on mesenchymal lineage adult stem cells to discover and manufacture therapeutic products that promote tissue repair and modulate immune responses. Its commercial product is Ryoncil (remestemcel-L-rknd), which is approved in the United States for treating steroid-refractory acute graft-versus-host disease in pediatric patients. In addition, Mesoblast is advancing clinical pipeline candidates including rexlemestrocel-L for degenerative disc disease and cardiovascular conditions. The company primarily serves healthcare providers, clinical transplant centers, and patients with serious inflammatory and cardiovascular conditions.
Operating with a corporate presence across Australia and the United States, Mesoblast employed 108 workers as of mid-2026. The company maintains in-house research laboratories while outsourcing therapeutic product manufacturing to third-party contract partners such as Lonza. Mesoblast is dual-listed on the Australian Securities Exchange and Nasdaq, with its global registered headquarters located in Melbourne, Victoria, Australia.
Summary of the business section of Mesoblast's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MESOBLAST LTD
- Founded
- 2004
- Headquarters
- Melbourne, Victoria, C3
- Address
- Level 38, 55 Collins Street 3000
- Phone
- 613 9639 6036
- Website
- mesoblast.com
- Employees
- 108, Jun 30, 2026
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- C3
- Fiscal year ends
- June 30
- Auditor
- PricewaterhouseCoopers, Melbourne, Australia
Stock & identifiers
- Ticker
- MESO
- Other tickers
- MEOBF
- Exchange
- Nasdaq
- IPO date
- Nov 13, 2015
- Shares outstanding
- 1.30B, Jun 30, 2026
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-2 reverse, Jan 10, 2024
- SEC CIK
- 1345099
- CUSIP
- 590717401
- ISIN
- US5907174016
- LEI
- 529900J5ALF3JG921927
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Silviu Itescu | CEO and Managing Director | 78,958,928 |
| Eric Allen Rose | Chief Medical Officer,Director | 714,720 |
| James Michael Obrien | Chief Financial Officer | – |
| Lynette Elizabeth Cobley | Director | 63,000 |
| Gregory George | Director | 162,154,002 |
| William Murray Burns | Director | 226,250 |
| Philip James Facchina | Director | 123,220 |
| Jane Catherine Bell | Director | 622,492 |
| Philip R. Krause | Director | 287,500 |
Employees
Headcount reported in annual reports
“• Mesoblast’s size and stage in its growth cycle: it is a commercial stage biotechnology company with 108 employees as of June 30, 2026, limited manufacturing and a recently FDA approved product in the United States.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 13, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 9, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |